Oncolytics Reports Progress In REO 033 Trial, Plans FDA Meeting Ahead; Shares Jump

Oncolytics Biotech (ONCY) issued a clinical and regulatory update on REO 033, its study evaluating pelareorep in combination for second-line treatment of RAS-mutant, microsatellite-stable (MSS) patients. No efficacy, safety, or milestone numbers were included in the provided excerpt, so near-term implications appear limited.

Analysis

Oncolytics Biotech (ONCY) issued a clinical and regulatory update on REO 033, its study evaluating pelareorep in combination for second-line treatment of RAS-mutant, microsatellite-stable (MSS) patients. No efficacy, safety, or milestone numbers were included in the provided excerpt, so near-term implications appear limited.